Bioengineered ears win first place at World Technology Summit

A method for bioengineering living human ears garnered a first-place award at the World Technology Summit in New York City, Nov. 15.

Academia: Loosen patent protection for diseases of poor

Universities should share discoveries crucial to combating diseases plaguing people in poverty, assert two Cornell scientists in a special issue of Nature.

With incubator’s help, ArcScan may see clear success

ArcScan, which signed on as the newest tenant Oct. 15 at Cornell's Kevin M. McGovern Family Center for Venture Development incubator, becomes the first company there whose medical device was developed at Weill Cornell Medical College.

Gold-plated nano-bits find, destroy cancer cells

Like nano-scale Navy Seals, Cornell scientists have merged tiny gold and iron oxide particles so that these alloyed allies can kill cancer cells with infrared heat.

Lucks, Seandel are NIH 'New Innovators'

Julius Lucks, assistant professor of chemical and biomolecular engineering, and Marco Seandel, assistant professor of cell and developmental biology in surgery at Weill Cornell Medical College, are NIH "New Innovators."

Fennie, Nirenberg named MacArthur Fellows

Craig Fennie, assistant professor of applied and engineering physics, and Sheila Nirenberg, associate professor of physiology and biophysics at Weill Cornell Medical College, have been named 2013 MacArthur Fellows.

Yahoo!'s Kathy Savitt to speak at NYC summit, Oct. 11

Kathy Savitt ’85, chief marketing officer at Yahoo!, will be the keynote speaker at the Cornell Entrepreneurship Summit NYC Oct. 11, hosted by Entrepreneurship@Cornell.

'Cornell Now' sets fundraising records in FY 2013

Cornell closed fiscal 2013 with a record-breaking $475 million in cash gifts to the “Cornell Now” campaign, including $278.1 million for the Ithaca campus, its highest ever in cash contributions.

$100M gift launches new Weill Cornell campaign

Weill Cornell Medical College has received a $100 million gift from longtime benefactors Joan and Sanford I. Weill to launch a $300 million capital campaign dedicated to using the most advanced scientific approaches to rapidly translate research breakthroughs into innovative treatments and therapies for patients.